Latest news
IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib - Pharmaceutical TechnologyPharmaceutical Technology · Mon, 03 Aug 2026 11:22:18 GMTRatio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPO - Endpoints NewsEndpoints News · Fri, 31 Jul 2026 14:59:00 GMTIMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand - marketscreener.commarketscreener.com · Fri, 31 Jul 2026 10:50:46 GMTIMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand - The Manila TimesThe Manila Times · Fri, 31 Jul 2026 08:06:11 GMTEupraxia Pharma Partners with Pharmanovia to License Senaparib in 66 Countries Including EU; Shares Surge Over 12% - finance.biggo.comfinance.biggo.com · Thu, 30 Jul 2026 07:00:00 GMT